Skip to main content
. 2017 Jun 26;1(15):1159–1166. doi: 10.1182/bloodadvances.2017008268

Figure 1.

Figure 1.

Treatment-free survival for patients receiving standard- vs reduced-dose rituximab prophylaxis. There was no difference in median treatment-free survival between standard-dose and reduced-dose groups: 29 vs 25 months, respectively (P = .25 log-rank test).